Human CCP antibody ELISA Kit

Rheumatoid arthritis (RA) is one of the most common autoimmune diseases. It is characterized by a progressive inflammation of the joints, leading to gradual damage and loss of their function. Early diagnosis of RA and immediate onset of an appropriate treatment is essential for prevention of complete joint damage. It has been demonstrated in numerous studies that antibodies against citrullinated peptides from enolase, fibrinogen and especially vimentin occur in RA patients, and autoantibodies against cyclic citrullinated peptide (Anti-CCP) are sensitive and specific diagnostic markers for RA. They correlate with an erosive course of disease with severe joint damage and extraarticular manifestations. In addition to rheumatoid factors, autoantibodies against citrullinated peptides and proteins have proven to be valuable tools for the serological diagnosis of early RA. They have become a critical component of the 2010 ACR criteria for the classification of RA, and account for three of the six points required to verify a diagnosis of RA. Anti-CCP detects autoantibodies very early– sometimes even years before symptoms become evident. Persons without symptoms but with an increased Anti-CCP antibody titre are at high risk for future RA development. Furthermore, a positive result is predictive for a severe course of RA. Therefore, Anti-CCP is an effective tool for rapid and precise routine diagnosis and favours immediate implementation of treatment